Australia's PharmAust hits over 3-yr high on partnering with MND specialist

Neurizon Therapeutics

16/01/2024 02:18

** Shares of Australia's PharmAust  PAA.AX  rise as much as
7.8% to A$0.140, their highest since Oct. 21, 2020
    ** Biotechnology co says it has partnered with clinical
study design specialist Berry Consultants to design and analyse
the planned adaptive phase 2/3 clinical study for monepantel in
patients with Motor Neurone Disease
    ** About 1,573,829 shares change hands, compared with the
30-day average volume of 490,912 shares
    ** Stock has risen 17.4% so far this year after surging
79.7% in 2023

 (Reporting by Megha Rani in Bengaluru)
 ((Megha.Rani2@thomsonreuters.com;))